158 related articles for article (PubMed ID: 26347037)
1. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.
Canals I; Benetó N; Cozar M; Vilageliu L; Grinberg D
Sci Rep; 2015 Sep; 5():13654. PubMed ID: 26347037
[TBL] [Abstract][Full Text] [Related]
2. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses.
Kaidonis X; Liaw WC; Roberts AD; Ly M; Anson D; Byers S
Eur J Hum Genet; 2010 Feb; 18(2):194-9. PubMed ID: 19690583
[TBL] [Abstract][Full Text] [Related]
3. Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation.
Busse M; Feta A; Presto J; Wilén M; Grønning M; Kjellén L; Kusche-Gullberg M
J Biol Chem; 2007 Nov; 282(45):32802-10. PubMed ID: 17761672
[TBL] [Abstract][Full Text] [Related]
4. Reduced Expression of EXTL2, a Member of the Exostosin (EXT) Family of Glycosyltransferases, in Human Embryonic Kidney 293 Cells Results in Longer Heparan Sulfate Chains.
Katta K; Imran T; Busse-Wicher M; Grønning M; Czajkowski S; Kusche-Gullberg M
J Biol Chem; 2015 May; 290(21):13168-77. PubMed ID: 25829497
[TBL] [Abstract][Full Text] [Related]
5. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.
Dziedzic D; Wegrzyn G; Jakóbkiewicz-Banecka J
Eur J Hum Genet; 2010 Feb; 18(2):200-5. PubMed ID: 19690584
[TBL] [Abstract][Full Text] [Related]
6. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.
Kloska A; Jakóbkiewicz-Banecka J; Narajczyk M; Banecka-Majkutewicz Z; Węgrzyn G
Metab Brain Dis; 2011 Mar; 26(1):1-8. PubMed ID: 21305347
[TBL] [Abstract][Full Text] [Related]
7. A new biochemical subtype of the Sanfilippo syndrome: characterization of the storage material in cultured fibroblasts of Sanfilippo C patients.
Kresse H; Von Figura K; Klein U
Eur J Biochem; 1978 Dec; 92(2):333-9. PubMed ID: 153835
[TBL] [Abstract][Full Text] [Related]
8. Glycosaminoglycans and mucopolysaccharidosis type III.
Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G
Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513
[TBL] [Abstract][Full Text] [Related]
9.
De Pasquale V; Esposito A; Scerra G; Scarcella M; Ciampa M; Luongo A; D'Alonzo D; Guaragna A; D'Agostino M; Pavone LM
J Med Chem; 2023 Feb; 66(3):1790-1808. PubMed ID: 36696678
[TBL] [Abstract][Full Text] [Related]
10. Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches.
Benetó N; Vilageliu L; Grinberg D; Canals I
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105639
[TBL] [Abstract][Full Text] [Related]
11. Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion.
Marques C; Poças J; Gomes C; Faria-Ramos I; Reis CA; Vivès RR; Magalhães A
J Biol Chem; 2022 Nov; 298(11):102546. PubMed ID: 36181793
[TBL] [Abstract][Full Text] [Related]
12. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
[TBL] [Abstract][Full Text] [Related]
13. EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner.
Nadanaka S; Zhou S; Kagiyama S; Shoji N; Sugahara K; Sugihara K; Asano M; Kitagawa H
J Biol Chem; 2013 Mar; 288(13):9321-33. PubMed ID: 23395820
[TBL] [Abstract][Full Text] [Related]
14. Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode alpha 1,4- N-acetylglucosaminyltransferases that likely are involved in heparan sulfate/ heparin biosynthesis.
Kim BT; Kitagawa H; Tamura J; Saito T; Kusche-Gullberg M; Lindahl U; Sugahara K
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7176-81. PubMed ID: 11390981
[TBL] [Abstract][Full Text] [Related]
15. Secondary storage of dermatan sulfate in Sanfilippo disease.
Lamanna WC; Lawrence R; Sarrazin S; Esko JD
J Biol Chem; 2011 Mar; 286(9):6955-62. PubMed ID: 21193389
[TBL] [Abstract][Full Text] [Related]
16. Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B.
Yu WH; Zhao KW; Ryazantsev S; Rozengurt N; Neufeld EF
Mol Genet Metab; 2000 Dec; 71(4):573-80. PubMed ID: 11136549
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.
Pshezhetsky AV
Autophagy; 2016 Jun; 12(6):1059-60. PubMed ID: 25998837
[TBL] [Abstract][Full Text] [Related]
18. Exostosin-like 2 regulates FGF2 signaling by controlling the endocytosis of FGF2.
Nadanaka S; Kitagawa H
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):791-799. PubMed ID: 29305908
[TBL] [Abstract][Full Text] [Related]
19. Sanfilippo syndrome: a mini-review.
Valstar MJ; Ruijter GJ; van Diggelen OP; Poorthuis BJ; Wijburg FA
J Inherit Metab Dis; 2008 Apr; 31(2):240-52. PubMed ID: 18392742
[TBL] [Abstract][Full Text] [Related]
20. EXTL2 controls liver regeneration and aortic calcification through xylose kinase-dependent regulation of glycosaminoglycan biosynthesis.
Nadanaka S; Kitagawa H
Matrix Biol; 2014 Apr; 35():18-24. PubMed ID: 24176719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
